Finiac
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's ...
RISK EFFICIENCY
0.09
AbbVie Inc's risk efficiency is 0.09, which is OK. By comparison, the S&P500 is -0.43.
View full risk analysis for AbbVie Inc
DSCORE
2.38%
AbbVie Inc's dScore is 2.38% , which is less volatile than the S&P500 (2.74%).
View full volatility analysis for AbbVie Inc
GROWTH
1.80%
AbbVie Inc has grown by 1.8% over the past year. By comparison, the S&P500 has lost -11.31%.
Increasing quickly over the past 4 weeks.
View full growth analysis for AbbVie Inc
View more portfolios
BT Roth IRA
12 Assets
PS_CapEff_Momentum
9 Assets
George Yee
RiskSmith Livestream Portfolio
11 Assets
Livestream_220321
drrms
SuperI
10 Assets